Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial
Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial
复制标题
白藜芦醇改善非酒精性脂肪肝患者的胰岛素抵抗、葡萄糖和脂质代谢：一项随机对照试验
DOI：
10.1016/j.dld.2014.11.015
复制
发表时间：
2015-03-01
影响因子：
4.5
通讯作者：
Mi, Mantian
中科院分区：
文献类型：
--
作者：
Chen, Shihui;Zhao, Xiaolan;Mi, Mantian
背景：非酒精性脂肪肝是一个全球性的主要健康问题。白藜芦醇是一种存在于可食用植物中的天然多酚，具有多种生化和生理作用。目的：方法：采用随机双盲、安慰剂对照的方法，对60例非酒精性脂肪性肝病患者分别口服安慰剂胶囊2粒（安慰剂组）和白藜芦醇胶囊2粒（白藜芦醇组），每日2次，疗程3个月。比较治疗前后肝脏超声成像、人体测量学特征、血清肝酶、胰岛素、葡萄糖、C肽、血脂和炎症相关细胞因子。与安慰剂组相比，白藜芦醇显著降低天冬氨酸转氨酶、葡萄糖和低密度脂蛋白胆固醇[-6.00（-9.00，-3.00）IU/L，-0.64 +/- 0.31 mmol/L，-0.41 +/- 0.35 mmol/L，P
Background: Non-alcoholic fatty liver disease is a major health problem worldwide. Resveratrol is a natural polyphenol found in edible plants that has a variety of biochemical and physiological effects. Aims: To evaluate the effect of resveratrol on insulin resistance, glucose and lipid metabolism in nonalcoholic fatty liver disease.Methods: Double-blind, randomized, placebo-controlled trial: 60 subjects with non-alcoholic fatty liver disease were given 2 placebo capsules (placebo group) or 2 150 mg resveratrol capsules (resveratrol group) twice daily for three months. Liver ultrasound imaging, anthropometric profile, serum liver enzymes, insulin, glucose, C-peptide, lipid profile, and inflammation-related cytokines were compared pre and post-treatment.Results: Compared with the placebo group, resveratrol significantly decreased aspartate aminotransferase, glucose and low-density lipoprotein cholesterol [-6.00 (-9.00, -3.00) IU/L, -0.64 +/- 0.31 mmol/L, and -0.41 +/- 0.35 mmol/L, respectively, P